Tagged with Access

LatAm In a wide-ranging interview, AbbVie’s Flavio Devoto outlines some of the key access challenges and opportunities in the diverse Latin American pharma market, his approach to being a transformational leader while balancing demands from headquarters with realities on the ground, and the enduring importance of LatAm to the global group.…

Pharma Legal Handbook 1. Which are the main actors involved in public procurement and tendering? There is a high degree of decentralisation in public procurement in Spain. Regarding the public procurement and tendering services of medicinal products there are actors involved at a national level (MOH), regional level (the governments of the Autonomous…

Greece Merck Greece’s Susan King-Barnardo outlines how she navigated the affiliate through the challenging waters of COVID-19, the unique market access challenges that innovative pharma is facing in Greece, Merck’s burgeoning clinical trial footprint in the country, and her approach to fostering diversity, equity, and inclusion.   There is a lot…

Global During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in arms about protecting the intellectual property (IP) of their innovative medicines. But there is an alternative, says Charles Gore from…

South Africa Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as 70 to 90 percent of the medicines consumed there. As the COVID-19 pandemic further demonstrated this dependence and the vulnerability…

Global Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now in the rear-view mirror for much of the world, Shaw questions whether the lessons and progress that the pandemic brought…

Portugal Part of PharmaBoardroom’s new country-focused series on market access and health technology assessment (HTA), this piece gives the lowdown on post-market approval processes and regulations in Portugal. Buy The Pharma Legal Handbook: Market Access & HTA – Portugal here for £359.   What are the pricing principles and processes in your…

Global Over the past year, PharmaBoardroom has spoken to pharma executives the world over, collecting unique perspectives from all sides of the industry. Here are the ten most-read interviews of 2022 that range from conversations with one of Korea’s top CDMOs to the American generics association and the Italian regulatory agency,…

Europe Based on current discussions by the European Commission, launch conditionalities would not account for the distinct nature of small and mid-sized companies, OMPs and ATMPs. EUCOPE’s Alexander Natz breaks down this aspect of the revision of the general pharmaceutical legislation and why it would prove unsustainable for smaller companies and…

Greece IFET is a unique institution within Greece that acts as the country’s mechanism for securing access to rare disease therapies not available in the market. The organisation also works to combat drug shortages in the country and played a key role in Greece’s COVID-19 pandemic response as the contracting authority…

LatAm Yaneth Giha of FIFARMA – the leading association for the innovative pharmaceutical industry in Latin America – gives a bird’s-eye overview on some of the key trends in LatAm healthcare, from regulatory and access challenges to the impact of the COVID-19 pandemic, the region’s potential as a clinical trials hub,…

Greece Michael Himonas of SFEE, the umbrella pharmaceutical association of 40 global innovative biopharma companies and 20 local companies in Greece, explains how the country’s pharmaceutical clawback and rebate system is restricting the growth of the industry and ultimately limiting and delaying patient access to medicines. However, Himonas is also keen…